Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).
暂无分享,去创建一个
K. Ogan | V. Master | O. Kucuk | W. Harris | M. Bilen | H. Kissick | Yuan Liu | B. Carthon | M. Alemozaffar | G. Russler | S. Caulfield | J. Shabto | D. Martini | D. Ravindranathan | Meredith R. Kline | E. Hitron